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Governments rightly request the advice
of scientists on matters of fact that affect
the public good, from climate change to
cancer screening. Scientists must then
assess available data and present recom-
mendations based on the data. But what is
the role of scientists when politicians see
these recommendations as inconvenient?
In mid-November 2009 the United
States Preventive Services Task Force
(USPSTF), which reviews scientific evi-
dence to develop recommendations for the
US health care community, revised their
recommendations to say that women
need not generally begin mammographic
screening for breast cancer until age 50
[1]. This revision, which brings the Task
Force’s recommendations closer to those
of the WHO, the UK, and the American
College of Physicians, touched off a
political firestorm in the US. The new
recommendations amounted to a change
in the evidence-based rating on screening
women between ages 40 and 50 from
grade B (recommended as likely to be of
moderate benefit) to grade C (recom-
mended against as a routine service, as
net benefit is likely to be small, although
there may be considerations that support
providing the service in an individual
patient). The US news media erupted in
reports that this change in rating had
confused women, ignored expert opinion,
and perhaps even revealed government
intentions to ration health care. Taken by
surprise and facing potential embarrass-
ment over an issue related to health care
reform, the Obama administration dis-
tanced itself from the Task Force, with the
Secretary of Health and Human Services
commenting that its members had been
appointed by the Bush administration.
The Task Force members, some of whom
took exception to this categorization, stood
by their findings but admitted that they
might have done a better job of commu-
nicating them.
The Task Force, composed of primary
care clinicians with expertise in disease
prevention and evidence-based medicine
and convened under the federal Agency
for Health Research and Quality (AHRQ),
has been developing practical recommen-
dations [2] since 1984. These recommen-
dations can influence which preventive
interventions US insurance plans will
cover. Established to be independent of
shifting politicalwinds and privateinterests,
the Task Force provides a model for how
comparative effectiveness research to im-
prove the evidence base for practicing
medicine can proceed in a country where
the influence of commercial interests on
clinical guidelines is an ongoing issue.
A few days after the recommendations’
release, Task Force Vice Chair Diana
Petitti stated: ‘‘So, what does this mean if
you are a woman in your 40s? You should
talk to your doctor and make an informed
decision about whether mammography is
right for you based on your family history,
general health, and personal values’’ [3].
Nonetheless, within weeks of the Novem-
ber guideline announcement, the US
Senate acted unanimously to amend its
health care bill to repudiate the Task
Force recommendation [4]. One might
argue that this action was necessary in the
face of popular outcry to avoid irreversible
damage to the greater goal of health care
reform. Yet the very health care bill that
the Senate amended already included
language providing that comparative ef-
fectiveness research should proceed not
along the existing model of unbiased
panels within AHRQ, but under a new
nongovernment institute overseen by a
committee of 19 members including six
from the private insurance and pharma-
ceutical industries and potentially only one
from AHRQ itself [5]. It appears that the
legislators, having found it politically
advisable in the short term to second-
guess the Task Force on the scientific
evidence for breast cancer screening, were
prepared in the long term to limit the role
of unbiased experts in assessing medical
evidence more broadly, apparently with
an expectation that expanded input from
the industries that profit most from health
care would improve the process. Surely
evidence-based medicine deserves better
than a push out of the frying pan of
partisan politics into the fire of vested
interests.
The US government was not the only
one to find itself in political turmoil over
the medical evidence base. A few weeks
prior to the USPSTF announcement, the
UK Home Secretary asked David Nutt to
resign as chair of the Advisory Council on
the Misuse of Drugs [6]. Nutt, a professor
at Imperial College London, had given
a lecture challenging the classification
scheme that determines legal penalties
for drug use in the UK, noting that the
classification of some drugs does not reflect
the evidence for their potential to cause
harm. (For example, harm ratings rank
alcohol and tobacco as more harmful than
the illegal drugs LSD, ecstasy, and canna-
bis [7].) Nutt subsequently commented, ‘‘I
have repeatedly stated [cannabis] is not
safe, but that the idea that you can reduce
use through raising the classification in the
Misuse of Drugs Act from class C to class
B—where it had previously been placed,
but thus now increasing the maximum
penalty for possession for personal use to 5
years in prison—is implausible’’ [8]. The
Home Office, for their part, expressed
‘‘surprise and disappointment over Profes-
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to give the public clear messages about the
dangers of drugs,’’ and confirmed that ‘‘we
remain determined to crack down on all
illegal substances and minimise their harm
to health and society as a whole.’’ Here, as
in the case of cancer screening in the US,
the conflict appears to be less about the
quality of the evidence than about how –
and even whether – scientists are to
communicate evidence on politically vol-
atile topics to the public.
In an enlightened society, surely science
must serve and enhance the public good,
and even the best medical research will not
attain this goal until its significance
reaches policymakers and the public in a
way that leads to improvements in health.
If science is to offer anything over opinion
polls, scientists must report unbiased
observations in an objective fashion,
whether or not the data are comforting,
expected, or even easily understood.
Scientists cannot selectively emphasize
the aspects of their work that will meet
with the widest approval, as politicians
sometimes do. Nonetheless, scientists—
particularly those invited by governments
to provide expertise—bear responsibility
for communicating their work with sensi-
tivity to its context and anticipated impact.
This kind of attention to public interpre-
tation of their work may not be what many
scientists are trained for or desire, but
without it there seems little hope that
scientific evidence—particularly when it
conflicts with the goals of politicians—will
emerge beyond barriers of indifference,
suspicion, or even hostility and appropri-
ately inform policy.
But however diligently scientists work to
ensure the integrity of their work and the
accuracy of its public perception, scientists
alone cannot realize the potential of
science to improve society. For real
progress to occur, those with power to
implement change must act on the evi-
dence. Politicians must not ignore nor
attempt to discredit legitimate science that
doesn’t happen to support their political
goals; to do so erodes public trust not only
in scientists but in politicians themselves.
In the case of health research, politicians
must remember that society encompasses
not only the corporate engines of econom-
ic growth and decline, but also individuals
whose lives depend on the quality of health
care data.
If governments are to engage in reform
that improves health, and not only the
economic structures through which health
care is provided, those governments must
develop and support systems to judge the
quality of health research independent of
vested interests and political expedience.
Informed citizens should expect and
require their governments to continue
inviting independent scientists on board,
to heed their advice in navigating, and not
to jettison scientific evidence when weath-
ering a political storm.
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